U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H12Cl2N2O5
Molecular Weight 323.129
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORAMPHENICOL

SMILES

OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O

InChI

InChIKey=WIIZWVCIJKGZOK-RKDXNWHRSA-N
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1

HIDE SMILES / InChI

Molecular Formula C11H12Cl2N2O5
Molecular Weight 323.129
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Chloramphenicol is a broad-spectrum antibiotic that was first isolated from Streptomyces venezuelae in 1947. The drug was subsequently chemically synthesized. It has both a bacteriostatic and bactericidal effect; in the usual therapeutic concentrations it is bacteriostatic. Chloramphenicol is used for the treatment of serious gram-negative, gram-positive, and anaerobic infections. It is especially useful in the treatment of meningitis, typhoid fever, and cystic fibrosis. It should be reserved for infections for which other drugs are ineffective or contraindicated. Chloramphenicol, a small inhibitor of bacterial protein synthesis, is active against a variety of bacteria and readily enters the CSF. It has been used extensively in the last decades for the treatment of bacterial meningitis. In industrialized countries, chloramphenicol is restricted mostly to topical uses because of the risk of induction of aplastic anemia. However, it remains a valuable reserve antibiotic for patients with allergy to β-lactam antibiotics or with CNS infections caused by multiresistant pathogens.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CHLOROPTIC

Approved Use

Indications and Usage In accord with the concepts in the Warning Box and this section, chloramphenicolmust be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. However, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests. The decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional concepts contained in the Warning Box above. 1. Acute infections caused by Salmonella typhi* It is not recommended for the routine treatment of the typhoid carrier state. 2. Serious infections caused by susceptible strains in accordance with the concepts expressed above: a) Salmonella species b) H. influenzae, specially meningeal infections c) Rickettsia d) Lymphogranuloma-psittacosis group e) Various gram-negative bacteria causing bacteremia, meningitis, or other serious gram-negative infections f) Other susceptible organisms which have been demonstrated to be resistant to all other appropriate antimicrobial agents. 3. Cystic fibrosis regimens *In treatment of typhoid fever some authorities recommend that chloramphenicol be administered at therapeutic levels for 8 to 10 days after the patient has become afebrile to lessen the possibility of relapse.

Launch Date

1968
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
16.9 μg/mL
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
59.1 μg × h/mL
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
500 mg 4 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.1 h
25 mg/kg 4 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
2.2 h
25 mg/kg 4 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CHLORAMPHENICOL SUCCINATE serum
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 4 times / day multiple, ophthalmic
Recommended
Dose: 0.5 %, 4 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 4 times / day
Sources:
unhealthy, 0.5 - 12 years
n = 163
Health Status: unhealthy
Condition: acute infective conjunctivitis
Age Group: 0.5 - 12 years
Sex: unknown
Population Size: 163
Sources:
Other AEs: Swollen eyelid...
Other AEs:
Swollen eyelid (1 patient)
Sources:
0.25 g 1 times / 3 months multiple, intramuscular
Recommended
Dose: 0.25 g, 1 times / 3 months
Route: intramuscular
Route: multiple
Dose: 0.25 g, 1 times / 3 months
Sources:
unhealthy, 11 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 11 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
70 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 70 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 70 mg/kg, 1 times / day
Co-administed with::
(meropenem)
120 mg/kg/day
Sources:
unhealthy, 15 years
n = 1
Health Status: unhealthy
Condition: Cystic Fibrosis and infection
Age Group: 15 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hyperlactatemia...
AEs leading to
discontinuation/dose reduction:
Hyperlactatemia (1 patient)
Sources:
3 g 1 times / day multiple, intravenous
Recommended
Dose: 3 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 23 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 23 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
2.5 g 1 times / day multiple, intravenous
Recommended
Dose: 2.5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 g, 1 times / day
Sources:
unhealthy, 27 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 27 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
1 g 1 times / day multiple, parenteral
Recommended
Dose: 1 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 39 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 39 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
750 mg 4 times / day steady, intravenous
Recommended
Dose: 750 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 750 mg, 4 times / day
Co-administed with::
tobramycin
nafcillin
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: purulent drainage from the surgical wound
Age Group: 54 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
4 g 1 times / day multiple, intravenous
Recommended
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy, 61 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 61 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
1 g 1 times / day multiple, intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 68 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 68 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 4, 1 patient)
Sources:
2 g 1 times / day multiple, parenteral
Recommended
Dose: 2 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 71 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Aplastic anemia...
AEs leading to
discontinuation/dose reduction:
Aplastic anemia (grade 5, 1 patient)
Sources:
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
unhealthy, adult
n = 23
Health Status: unhealthy
Condition: cancer patients with (EGFRI)-induced papulopustular rash
Age Group: adult
Sex: unknown
Population Size: 23
Sources:
AEs

AEs

AESignificanceDosePopulation
Swollen eyelid 1 patient
0.5 % 4 times / day multiple, ophthalmic
Recommended
Dose: 0.5 %, 4 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 4 times / day
Sources:
unhealthy, 0.5 - 12 years
n = 163
Health Status: unhealthy
Condition: acute infective conjunctivitis
Age Group: 0.5 - 12 years
Sex: unknown
Population Size: 163
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
0.25 g 1 times / 3 months multiple, intramuscular
Recommended
Dose: 0.25 g, 1 times / 3 months
Route: intramuscular
Route: multiple
Dose: 0.25 g, 1 times / 3 months
Sources:
unhealthy, 11 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 11 years
Sex: F
Population Size: 1
Sources:
Hyperlactatemia 1 patient
Disc. AE
70 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 70 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 70 mg/kg, 1 times / day
Co-administed with::
(meropenem)
120 mg/kg/day
Sources:
unhealthy, 15 years
n = 1
Health Status: unhealthy
Condition: Cystic Fibrosis and infection
Age Group: 15 years
Sex: F
Population Size: 1
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
3 g 1 times / day multiple, intravenous
Recommended
Dose: 3 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 3 g, 1 times / day
Sources:
unhealthy, 23 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 23 years
Sex: M
Population Size: 1
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
2.5 g 1 times / day multiple, intravenous
Recommended
Dose: 2.5 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 2.5 g, 1 times / day
Sources:
unhealthy, 27 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 27 years
Sex: F
Population Size: 1
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
1 g 1 times / day multiple, parenteral
Recommended
Dose: 1 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 39 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 39 years
Sex: M
Population Size: 1
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
750 mg 4 times / day steady, intravenous
Recommended
Dose: 750 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 750 mg, 4 times / day
Co-administed with::
tobramycin
nafcillin
Sources:
unhealthy, 54 years
n = 1
Health Status: unhealthy
Condition: purulent drainage from the surgical wound
Age Group: 54 years
Sex: M
Population Size: 1
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
4 g 1 times / day multiple, intravenous
Recommended
Dose: 4 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy, 61 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 61 years
Sex: M
Population Size: 1
Sources:
Aplastic anemia grade 4, 1 patient
Disc. AE
1 g 1 times / day multiple, intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, 68 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 68 years
Sex: F
Population Size: 1
Sources:
Aplastic anemia grade 5, 1 patient
Disc. AE
2 g 1 times / day multiple, parenteral
Recommended
Dose: 2 g, 1 times / day
Route: parenteral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: infection
Age Group: 71 years
Sex: F
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Carbon and nitrogen removal from a wastewater of an industrial dairy laboratory with a coupled anaerobic filter-sequencing batch reactor system.
2001
Disposition kinetics of florfenicol in goats by using two analytical methods.
2001 Apr
Randomised controlled trial of ketorolac in the management of corneal abrasions.
2001 Apr
Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells.
2001 Apr
The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal.
2001 Apr
Liposome-mediated DNA uptake and transient expression in Thermotoga.
2001 Feb
Molecular epidemiology of multiple drug resistant type 6B Streptococcus pneumoniae in the Northern Territory and Queensland, Australia.
2001 Feb
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.
2001 Feb
Determination of assay and impurities of gamma irradiated chloramphenicol in eye ointment.
2001 Feb
Vibrio parahaemolyticus associated with cholera-like diarrhea among patients in North Jakarta, Indonesia.
2001 Feb
Phytochemical and antimicrobial properties of constituents of "Ogwu Odenigbo", a popular Nigerian herbal medicine for typhoid fever.
2001 Feb
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
2001 Feb
Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia.
2001 Jan
Shigella and Salmonella strains isolated from children under 5 years in Gaborone, Botswana, and their antibiotic susceptibility patterns.
2001 Jan
Mesophyll-specific, light and metabolic regulation of the C4 PPCZm1 promoter in transgenic maize.
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
DNA circle formation in Neisseria gonorrhoeae: a possible intermediate in diverse genomic recombination processes.
2001 Jan
Adhesion to a polymeric biomaterial affects the antibiotic resistance of Staphylococcus epidermidis.
2001 Jan
New uses of older antibiotics.
2001 Jan
Molecular features determining lymphocyte reactivity in allergic contact dermatitis to chloramphenicol and azidamphenicol.
2001 Jan
Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli.
2001 Jan
Travel-associated Burkholderia pseudomallei infection (Melioidosis) in a patient with cystic fibrosis: a case report.
2001 Jan
Lack of evidence for chloramphenicol resistance in Neisseria meningitidis, Africa.
2001 Jan-Feb
[Lactobacillus paracasei endocarditis in an 18-yeard-old patient with trisomy 21, atrioventricular septal defect and Eisenmenger complex: therapeutic problems].
2001 Jan-Feb
A novel heat shock protein plays an important role in thermal stress management in cyanobacteria.
2001 Jul 6
Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain.
2001 Jun
Secretion of the virulence-associated Campylobacter invasion antigens from Campylobacter jejuni requires a stimulatory signal.
2001 Jun 1
Analysis of a conserved hydrophobic pocket important for the thermostability of Bacillus pumilus chloramphenicol acetyltransferase (CAT-86).
2001 Mar
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001 Mar
Antimicrobial susceptibility of Listeria monocytogenes isolated from meningoencephalitis in sheep.
2001 Mar
Antimicrobial resistance of Enterococci in Lebanon.
2001 Mar
Improved agar diffusion method for detecting residual antimicrobial agents.
2001 Mar
Clinical, laboratory, and epidemiologic features of murine typhus in 97 Texas children.
2001 Mar
In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes.
2001 Mar-Apr
Patterns of antibiotic resistance, serotype distribution, and patient demographics of Streptococcus pneumoniae in Hong Kong.
2001 Mar-Apr
Induction of complement sensitivity in Escherichia coli by citric acid and low pH.
2001 May
In vitro susceptibility of Vibrio spp. isolated from the environment.
2001 May
Chromate tolerant bacteria isolated from tannery effluent.
2001 May
Neisseria meningitidis with decreased susceptibility to penicillin in Ontario, Canada 1997-2000.
2001 May 1
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones.
2001 Spring
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
2001 Spring
Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods.
2001 Spring
Patents

Sample Use Guides

Chloramphenicol 0.5% Eye Drops
Route of Administration: Topical
The highest activity of chloramphenicol was documented for isolates of Stenotrophomonas maltophilia (76,5 % susceptible, MIC50 = 4 mg/L, MIC90 = 16 mg/L) and of Staphylococcus aureus (76,2 % susceptible, MIC50 = 8 mg/L, MIC90 = 16 mg/L).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:00:29 GMT 2023
Edited
by admin
on Fri Dec 15 15:00:29 GMT 2023
Record UNII
66974FR9Q1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORAMPHENICOL
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CHLORAMPHENICOL [MI]
Common Name English
CHLOROPTIC-P S.O.P. COMPONENT CHLORAMPHENICOL
Common Name English
NSC-3069
Code English
OPHTHOCHLOR
Brand Name English
CHLOROMYCETIN
Brand Name English
CHLORAMPHENICOL [MART.]
Common Name English
CHLORAMPHENICOL [HSDB]
Common Name English
MYCHEL
Brand Name English
Chloramphenicol [WHO-DD]
Common Name English
CHLORAMPHENICOL COMPONENT OF CHLOROMYXIN
Common Name English
CHLOROPTIC
Brand Name English
CHLORAMPHENICOL [USP-RS]
Common Name English
CHLORAMPHENICOLUM
HPUS   WHO-IP LATIN  
Common Name English
D-THREO-(-)-2,2-DICHLORO-N-(.BETA.-HYDROXY-.ALPHA.-(HYDROXYMETHYL)-P-NITROPHENETHYL)ACETAMIDE
Common Name English
CHLORAMPHENICOL [GREEN BOOK]
Common Name English
CHLORAMPHENICOL [WHO-IP]
Common Name English
2,2-DICHLORO-N-((1R,2R)-2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)ACETAMIDE
Systematic Name English
OPHTHOCORT COMPONENT CHLORAMPHENICOL
Common Name English
chloramphenicol [INN]
Common Name English
CHLORAMPHENICOL [ORANGE BOOK]
Common Name English
CHLORAMPHENICOL COMPONENT OF CHLOROMYCETIN HYDROCORTISONE
Common Name English
CHLORAMPHENICOL COMPONENT OF CHLOROPTIC-P S.O.P.
Common Name English
OPTOMYCIN
Brand Name English
NOVOMYCETIN
Common Name English
CHLORAMPHENICOL [VANDF]
Common Name English
CHLOROMYCETIN HYDROCORTISONE COMPONENT CHLORAMPHENICOL
Common Name English
ELASE-CHLOROMYCETIN COMPONENT CHLORAMPHENICOL
Common Name English
CHLORAMPHENICOL [USP MONOGRAPH]
Common Name English
CHLORAMPHENICOL [JAN]
Common Name English
CHLORAMPHENICOL COMPONENT OF ELASE-CHLOROMYCETIN
Common Name English
CHLORAMPHENICOLUM [HPUS]
Common Name English
SYNTHOMYCETIN
Common Name English
CHLORAMPHENICOL [IARC]
Common Name English
CHLORAMPHENICOLUM [WHO-IP LATIN]
Common Name English
CHLORAMPHENICOL [EP MONOGRAPH]
Common Name English
AMPHICOL
Brand Name English
CHLORAMPHENICOL COMPONENT OF OPHTHOCORT
Common Name English
CHLOROMYXIN COMPONENT CHLORAMPHENICOL
Common Name English
ECONOCHLOR
Brand Name English
ACETAMIDE, 2,2-DICHLORO-N-(2-HYDROXY-1-(HYDROXYMETHYL)-2-(4-NITROPHENYL)ETHYL)-, (R-(R*,R*))-
Common Name English
CHLOROFAIR
Brand Name English
Classification Tree Code System Code
WHO-VATC QD10AF03
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
NCI_THESAURUS C258
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC G01AA05
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC S03AA08
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QD06AX02
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QG01AA55
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QJ01BA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 524.390
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 530.41
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QS03AA08
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC D10AF03
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC D06AX02
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 520.390
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
IARC Chloramphenicol
WHO-VATC QJ51BA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QJ51RB01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QS02AA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
NDF-RT N0000175479
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
NDF-RT N0000175479
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 522.390
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC J01BA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
NDF-RT N0000175480
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QG01AA05
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC S01AA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 520.390A
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
LIVERTOX NBK548105
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-ATC S02AA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
WHO-VATC QS01AA01
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
CFR 21 CFR 520.390B
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
Code System Code Type Description
MESH
D002701
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
CAS
56-75-7
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
INN
977
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
NCI_THESAURUS
C363
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID7020265
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
HSDB
3027
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-287-4
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
PUBCHEM
5959
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
DRUG BANK
DB00446
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
MERCK INDEX
m3347
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL130
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
DAILYMED
66974FR9Q1
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
NSC
3069
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
ALANWOOD
chloramphenicol
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
LACTMED
Chloramphenicol
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
FDA UNII
66974FR9Q1
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
DRUG CENTRAL
589
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
CHEBI
17698
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
EVMPD
SUB06173MIG
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
SMS_ID
100000092772
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
WIKIPEDIA
CHLORAMPHENICOL
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
RS_ITEM_NUM
1107004
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY
RXCUI
2348
Created by admin on Fri Dec 15 15:00:29 GMT 2023 , Edited by admin on Fri Dec 15 15:00:29 GMT 2023
PRIMARY RxNorm
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
METABOLIC ENZYME -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME->WEAK INHIBITOR
COMPETITIVE INHIBITOR
Ki
TARGET ORGANISM->INHIBITOR
METABOLIC ENZYME -> NON-INHIBITOR
METABOLIC ENZYME -> NON-INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> NON-INHIBITOR
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INHIBITOR
MIXED INHIBITION
MAJOR
Ki
Related Record Type Details
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Colourless to greyish white or yellowish white, needle-like crystals or elongated plates or a crystalline powder; odourless.
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC